The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
me change notification emails
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
Description of Modification
Application Submission Deadline is changed to August 19, 2009.
Modification to Previous
Funding Opportunity Number:
Feb 01, 2009
Jun 18, 2009
Original Closing Date for Applications:
Jul 22, 2009
Current Closing Date for Applications:
Aug 19, 2009
Aug 21, 2009
Funding Instrument Type:
Category of Funding Activity:
Science and Technology and other Research and Development
Expected Number of Awards:
Estimated Total Program Funding:
Military Medical Research and Development
Cost Sharing or Matching Requirement:
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Dept. of the Army -- USAMRAA
The ARP CTA supports clinical trials with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism cannot be used for preclinical research studies. Refer to the Application Instructions and General Information, Appendix 6, for helpful information about distinguishing clinical trials and clinical research. The proposed clinical trial is expected to begin no later than 12 months after the award date. Areas of Interest (Revised for FY09): The FY09 ARP encourages applications that address critical needs of the autism community in the following areas:• Co-morbidity: (e.g., manifestations such as disorders [gastrointestinal, sleep, behavioral, speech/language], psychiatric, seizures, immune dysfunction, motor and sensory deficits, metabolic dysfunction, and effects of ASD on intellectual ability)• Predictors for Treatment Outcome: Identification of biomarkers, clinical characteristics, or other phenotypic markers that predict outcomes of a treatment (traditional or complementary and alternative), or populations that will or will not respond to a treatment.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
PA HELP: 301-619-7079; firstname.lastname@example.org
eReceipt HELP: 301-682-5507; email@example.com
CDMRP Help Desk
Synopsis Modification History
The following files represent the modifications to this synopsis
with the changes noted within the documents. The list of files is
arranged from newest to oldest with the newest file representing the
current synopsis. Changed sections from the previous document are shown
in a light grey background.